"But it was the first time I heard of the TB vaccine as a cancer treatment," she points out. And this immediately caught her ...

Over the years, BCG has been used as an immunotherapy for bladder cancer since the 1970s and remains the only FDA-approved first-line treatment for patients with non-muscle invasive bladder cancer.

There are few treatment options for patients who develop BCG-unresponsive bladder cancer, which raises the risk of the cancer spreading throughout the body. Around 40% of patients don’t respond ...

There are three types of intravesical immunotherapies for bladder cancer: BCG treatment is the most common immunotherapy for cancer and is often the first-line option for bladder cancer.

rBCG offers an alternative to TICE® BCG amid U.S. shortages, impacting bladder cancer treatment availability. FDA's Expanded Access Program allows investigational rBCG use when no satisfactory ...

Patient Diagnosed with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ Treated Once with Light-Activated Ruvidar(TM) ...

Cretostimogene monotherapy achieves a 75.5% complete response rate in high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients. The treatment maintains a 46% complete response at 12 ...

Up to 40% of patients with non-muscle-invasive bladder cancer do not respond to traditional immunotherapy for the condition, known as BCG treatment, which uses a weakened bacteria. In April 2024 ...

Surgery, chemotherapy, and radiation are some of the treatments for bladder cancer. Treatments used depend on your cancer’s stage and grade, and your age, overall health, and personal preferences.

Supply shortages of TICE BCG in the U.S. have become a significant impediment to the treatment of bladder cancer patients. In a recent Sermo survey of 100 U.S. urologists, 57 percent indicated ...

Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive ...